234 related articles for article (PubMed ID: 35604633)
1. EQ-5D-Y Value Set for Germany.
Kreimeier S; Mott D; Ludwig K; Greiner W;
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
[TBL] [Abstract][Full Text] [Related]
2. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
[TBL] [Abstract][Full Text] [Related]
3. Value Set for the EQ-5D-Y-3L in Hungary.
Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
[TBL] [Abstract][Full Text] [Related]
4. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
[TBL] [Abstract][Full Text] [Related]
5. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
6. A Value Set for the EQ-5D-Y-3L in the Netherlands.
Roudijk B; Sajjad A; Essers B; Lipman S; Stalmeier P; Finch AP
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):193-203. PubMed ID: 36216977
[TBL] [Abstract][Full Text] [Related]
7. EQ-5D-Y Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M;
Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
9. Estimating an EQ-5D-Y-3L Value Set for China.
Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
[TBL] [Abstract][Full Text] [Related]
10. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
11. An EQ-5D-Y-3L Value Set for Belgium.
Dewilde S; Roudijk B; Tollenaar NH; Ramos-Goñi JM
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):169-180. PubMed ID: 36316544
[TBL] [Abstract][Full Text] [Related]
12. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
13. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
14. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
15. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
[TBL] [Abstract][Full Text] [Related]
16. Valuation of the EQ-5D-3L in Russia.
Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
[TBL] [Abstract][Full Text] [Related]
17. German Value Set for the EQ-5D-5L.
Ludwig K; Graf von der Schulenburg JM; Greiner W
Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
[TBL] [Abstract][Full Text] [Related]
18. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
[TBL] [Abstract][Full Text] [Related]
20. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]